AU2265701A - Anti-hiv-1 conjugates for treatment of hiv disease - Google Patents
Anti-hiv-1 conjugates for treatment of hiv diseaseInfo
- Publication number
- AU2265701A AU2265701A AU22657/01A AU2265701A AU2265701A AU 2265701 A AU2265701 A AU 2265701A AU 22657/01 A AU22657/01 A AU 22657/01A AU 2265701 A AU2265701 A AU 2265701A AU 2265701 A AU2265701 A AU 2265701A
- Authority
- AU
- Australia
- Prior art keywords
- hiv
- conjugates
- treatment
- disease
- hiv disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17118799P | 1999-12-16 | 1999-12-16 | |
| US60171187 | 1999-12-16 | ||
| PCT/US2000/034032 WO2001043779A2 (en) | 1999-12-16 | 2000-12-15 | Anti-hiv-1 conjugates for treatment of hiv disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2265701A true AU2265701A (en) | 2001-06-25 |
Family
ID=22622858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU22657/01A Abandoned AU2265701A (en) | 1999-12-16 | 2000-12-15 | Anti-hiv-1 conjugates for treatment of hiv disease |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2265701A (en) |
| WO (1) | WO2001043779A2 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060078537A1 (en) * | 2001-12-21 | 2006-04-13 | Matthias Mack | Mono-and dual chemokine/cytokine constructs |
| CN1780907B (en) * | 2002-02-22 | 2011-06-15 | 原基因药物有限公司 | Anti-CCR5 antibody |
| CA2570735A1 (en) * | 2004-08-30 | 2006-03-09 | Schering Aktiengesellschaft | Treatment of hiv infection by t-cell modulation |
| TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
| TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
| KR101105610B1 (en) * | 2006-08-17 | 2012-01-18 | 에프. 호프만-라 로슈 아게 | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
| AU2007302294A1 (en) | 2006-09-29 | 2008-04-03 | F. Hoffmann-La Roche Ag | Antibodies against CCR5 and uses thereof |
| US20090143288A1 (en) | 2007-03-13 | 2009-06-04 | Roche Palo Alto Llc | Peptide-complement conjugates |
| AR067584A1 (en) * | 2007-07-20 | 2009-10-14 | Hoffmann La Roche | A CONJUGATE OF AN ANTIBODY AGAINST CD4 AND ANTIFUSOGENIC PEPTIDES |
| KR101671537B1 (en) | 2008-08-11 | 2016-11-01 | 넥타르 테라퓨틱스 | Multi-arm polymeric alkanoate Conjugates |
| WO2010028798A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
| WO2010028796A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
| WO2010028795A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
| WO2010028797A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
| US9163067B2 (en) * | 2008-10-06 | 2015-10-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | HIV-1 integrase derived stimulatory peptides interfering with integrase—Rev protein binding |
| RU2517084C2 (en) | 2010-08-06 | 2014-05-27 | Олег Ильич Эпштейн | Method and means for inhibiting production or enhancing protein p24 elimination |
| WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| US20140088021A1 (en) | 2011-05-27 | 2014-03-27 | Nektar Therapeutics | Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds |
| US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| WO2016054296A2 (en) * | 2014-09-30 | 2016-04-07 | California Institute Of Technology | Crosslinked anti-hiv-1 compositions for potent and broad neutralization |
| US10450368B2 (en) | 2015-03-19 | 2019-10-22 | Duke University | HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies) |
| EP3286212B1 (en) * | 2015-04-24 | 2021-06-02 | VIIV Healthcare UK (No.5) Limited | Polypeptides targeting hiv fusion |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| CA3221152A1 (en) * | 2021-06-10 | 2022-12-15 | Marzena PAZGIER | Antibody-cd4 conjugates and methods of using the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5871732A (en) * | 1990-11-27 | 1999-02-16 | Biogen, Inc. | Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection |
| WO1998000535A2 (en) * | 1996-06-28 | 1998-01-08 | Dana-Farber Cancer Institute | Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection |
| WO1998015569A1 (en) * | 1996-10-09 | 1998-04-16 | Dana-Farber Cancer Institute | Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection |
| DE19801265C1 (en) * | 1998-01-15 | 1999-08-12 | Deutsches Krebsforsch | Inhibition of CD95-independent apoptosis in AIDS |
| AU773175B2 (en) * | 1998-12-16 | 2004-05-20 | Progenics Pharmaceuticals, Inc. | Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto |
| CA2403718A1 (en) * | 2000-03-17 | 2001-09-27 | Panacos Pharmaceuticals, Inc. | A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins |
-
2000
- 2000-12-15 WO PCT/US2000/034032 patent/WO2001043779A2/en not_active Ceased
- 2000-12-15 AU AU22657/01A patent/AU2265701A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001043779A3 (en) | 2002-05-10 |
| WO2001043779A2 (en) | 2001-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2265701A (en) | Anti-hiv-1 conjugates for treatment of hiv disease | |
| AU2180400A (en) | A pharmaceutical combination for the treatment of depression | |
| AU2492600A (en) | Surgical handpiece | |
| AUPQ893200A0 (en) | Medical residue treatment | |
| AU6360400A (en) | Ceramic dental mill blanks | |
| AU4198500A (en) | Suture-passing forceps | |
| AU3469400A (en) | Pharmaceutical compositions for treatment of diseased tissues | |
| AU3009801A (en) | Combinations of medicaments for treating viral diseases | |
| AU2001265253A1 (en) | Treatment of hiv using hyperthermia | |
| AU5215300A (en) | Dental treatment area | |
| AU2495100A (en) | Surgical handpiece | |
| AU6715600A (en) | Pharmaceutical formulations | |
| AU7731700A (en) | Low dose ifn-gamma for treatment of disease | |
| AU2002219881A1 (en) | Methods and compositions for the treatment of human immunodeficiency virus infection | |
| AU2281601A (en) | Treatment of viral infections using levovirinTM | |
| AU7309900A (en) | Anti-irritant disposable diaper | |
| AU4977300A (en) | Pharmaceutical formulations | |
| AU1626101A (en) | Human transcriptomes | |
| AU1385801A (en) | Pharmaceutical formulations | |
| AU5394300A (en) | Tissue engineering | |
| AU3760900A (en) | Treatment of menstrual function | |
| AU7975500A (en) | Drug for treatment of immunodeficiency states | |
| AU1405001A (en) | Treatment of diseases | |
| AU2960000A (en) | Detection of human immunodeficiency virus | |
| AU4368800A (en) | Assay for hiv-1 infectivity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |